In the treatment of hepatocellular carcinoma (HCC), although surgical resection, interventional therapy, radiotherapy/chemotherapy, targeted therapy, immunotherapy, and liver transplantation are effective, the 5-year survival rate is still meager. The main reason is that HCC is more prone to recurrence and metastasis. Furthermore, HCC has an insidious onset and progresses slowly, and patients often miss the optimal time for treatment. MicroRNAs (miRNAs) are non-coding single-stranded RNAs first discovered in Caenorhabditis elegans in 1993. They are highly conserved and widely exist in animals, plants, and some viruses. miRNAs promote the degradation of target genes or inhibit the translation of target genes through complementary base pairing, thus achieving the post-transcriptional regulation of target genes. The pathological processes of many diseases, including cancer, metabolic diseases, and HCC, are regulated by miRNAs, which makes miRNAs potential biomarkers and therapeutic targets.
inflammatory diseases, and cardiovascular, are highly dependent on the regulation of miRNA.4–6

Over the past decades, there has been increasing research on the role of miRNAs in cancer.7 A large number of abnormally expressed miRNAs exist in HCC. MiRNAs expression proﬁles have potential as biomarkers for the diagnosis and prognosis of HCC.8 In-depth research of the expression of miRNAs and their regulatory mechanism in HCC is of great importance to guide early diagnosis, treatment, and prognosis of HCC. In this review, the regulatory role of miRNAs in the occurrence and development, diagnosis, treatment, and prognostic assessment of HCC will be elaborated, with emphasis on the regulation and related mechanisms of miRNAs on the occurrence and development of HCC.

2 | REGULATION OF HCC OCCURRENCE AND DEVELOPMENT BY MIRNAS

2.1 | MiRNAs and cellular biological processes in HCC

In HCC, miRNAs can act as promoters or suppressors to regulate multiple cellular biological processes such as proliferation, migration, invasion, and apoptosis.9 For example, miR-182-5p directly targeted the 3′ UTR of FoxO3a in surgically treated HCC patients, activating the Akt/FoxO3a pathway and promoting proliferation and migration of HCC cells.10,11 MiR-1225-5p level was decreased in HCC patients. Transfection with miR-1225-5p mimics inhibited the viability, proliferation, migration, and invasion of HCC cells and reduced the expression of matrix metalloproteinase 9 (MMP-9).12 MiR-199b-5p inhibited the proliferation of HCC cells through regulation of CDC24A to induce cell cycle arrest.13 The level of miR-222 in HCC patients with tumors larger than 5 cm was signiﬁcantly higher than that of patients with tumors smaller than 5 cm. Inhibition of miR-222 suppressed the proliferation and promoted the apoptosis of HCC cells.14 Other miRNAs, such as miR-217, miR-340, miR-206, miR-302a, and miR-30a-5p could regulate the biological processes of HCC cells by targeting different genes.15–19

Some miRNAs can regulate hepatocyte apoptosis through intrinsic and extrinsic pathways.20 In HBV-related HCC, miR-15a/miR-16-1 regulated anillin, which was essential for tumor growth, thereby affecting apoptosis of HCC cells.21 MiR-125b promoted HCC cells apoptosis and attenuated human HCC malignancy by targeting SIRT6.22 MiR-221/222 promoted HCC development by targeting apoptosis-related factor p53, signal transducers and activators of transcription 3 (STAT3), and nuclear factor xB (NF-xB).23 MiR-221/222 induced TNF-related apoptosis and ligand (TRAIL) resistance by modulating tumor suppressors phosphatase, tensin homomorphs located on chromosome 10 (PTEN), and tissue metalloproteinase inhibitor 3 during hepatocellular carcinogenesis. Moreover, the activation of Akt pathway and matrix metalloproteinase activity by miR-221/222 could promote the migration of HCC cells.24

2.2 | MiRNAs and angiogenesis in HCC

Some angiogenesis-related miRNAs were signiﬁcantly reduced in HCC, such as miR-15b, miR-125b, miR-423-3p, miR-424, miR-494, miR-497, miR-612, miR-637, and miR-1255b.25 MiR-130b-3p directly targeted HOXA5 to upregulate the expression of endothelial markers CD31 and CD34, thereby promoting HCC angiogenesis and ultimately leading to larger tumor size and shorter overall survival time.26 MiR-3064-5p induced the expression of anti-angiogenic endostatin via inhibiting the vascular endothelial growth factor A (VEGFA).27 MiR-20b regulated hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF) to promote HCC cell adaptation to different environments.28

Precise identiﬁcation of signaling molecules that play a vital role in angiogenesis is helpful for targeted therapy of HCC. Overexpression of miR-126 in HCC cells was found to reduce tumor volume, serum alanine aminotransferase and alpha-fetoprotein (AFP), and VEGF levels, suggesting that miR-126 can inhibit HCC angiogenesis.29 MiR-126 in combination with novel angiogenesis inhibitors may be developed into new targeted therapies.30 Vascular mimicry (VM) is a mode of angiogenesis, which tumor tissues nourish themselves.31

MiR-138-5p inhibited VM by targeting the HIF-1α/VEGFA pathway in HCC.32 A complex miRNAs-target RNAs interaction network inhibited VM formation in HCC by downregulating the circRNA7/miR7-5p/VE-Cadherin/Notch4 signaling pathway.33

2.3 | MiRNAs and cell tolerance in HCC

MiRNAs-target RNAs interaction network also mediates the therapeutic sensitivity of HCC cells.34 MiR-20a induced HCC cells radio-resistance via the PTEN/phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway.35 MiR-193a-3p improved the viability and proliferation of HCC cells after radiotherapy and chemotherapy.36 MiR-26b enhanced the radio-sensitivity of HCC cells by targeting erythropoietin-producing HCC A2.37 In addition, miR-320b, miR-203, miR-146a-5p, miR-1271-5p, and miR-621 could increase the radio-sensitivity of HCC cells.38–42 Fer-1 like family member 4 promoted E2F1-dependent NF-κB activation by inhibiting miR-106a-5p/miR-372-5p, thus leading to cisplatin resistance in HCC cells.43

As a multiple tyrosine protein kinase inhibitor, sorafenib is considered as a ﬁrst-line treatment for advanced HCC. However, drug resistance limits the clinical efﬁcacy of sorafenib. MiR-25 enhanced sorafenib resistance of HCC cells via inducing FBXW7-mediated autophagy, which might provide a therapeutic target for the treatment of HCC.44 The level of liver-speciﬁc miR-122 in sorafenib-resistant cells was signiﬁcantly reduced. MiR-122 could radiosensitize HCC cells by suppressing cyclin G1.45 Overexpression of miR-122 restored the sensitivity of HCC cells to sorafenib and induced apoptosis. In contrast, knockdown of miR-122 upregulated the expression of insulin-like growth factor 1 receptor and activated Ras/Raf/ERK signaling pathway, thereby mediating drug resistance in HCC cells.46
Sorafenib upregulated miR-375 level in HCC cells through the transcription factor ASH1, thereby inhibiting platelet-derived growth factor C (PDGFC) and exerting its anti-angiogenic effect. MiR-375 level was reduced in sorafenib-resistant HCC cells. The restoration of miR-375 partially sensitized drug-resistant cells to sorafenib through degradation of astrocyte elevated gene 1, suggesting that miR-375 was crucial for sorafenib tolerance and HCC angiogenesis.\textsuperscript{47}

MiR-221 was also over-expressed in sorafenib-resistant HCC cells. Sorafenib can drive the anti-apoptotic activity of miR-221; however, miR-221 can also participate in sorafenib-resistance by regulating caspase-3. The level of serum miR-221 reflected the reactivity of HCC cells to sorafenib. MiR-221 level was also elevated in that with high reactivity. Therefore, miR-221 may be a biomarker of sorafenib-reactivity in HCC patients.\textsuperscript{48}

2.4 | MiRNAs and tumor microenvironment in HCC

In addition to tumor cells, tumor microenvironment contains a large number of mesenchymal cells, including macrophages, cancer-associated fibroblasts (CAFs), endothelial cells, neutrophils, and so on. Macrophages are highly heterogeneous that can be polarized into different phenotypes by stimulating factors in the microenvironment. Classically activated M1-type macrophages are pro-inflammatory and anti-tumor, while alternatively activated M2-type macrophages are anti-inflammatory and pro-tumor. Tumor-associated macrophages (TAMs) usually present M2 phenotype and are associated with poor prognosis.\textsuperscript{59,50} Tumor-derived exosomes can regulate the polarization of TAMs through transporting miRNAs.\textsuperscript{51,52}

The regulation of TAMs by miRNAs mainly includes three aspects: differentiation, functional polarization, and cellular crosstalk.\textsuperscript{52} Macrophage-derived microvesicles carrying miR-223 mediated monocyte differentiation.\textsuperscript{51} In the presence of a granulocyte-macrophage colony-stimulating factor, miR-148a-3p promoted monocytes differentiate into macrophages through Notch signaling pathway.\textsuperscript{54} MiR-148b downregulation induced TAM infiltration and promoted HCC metastasis through colony-stimulating factor-1.\textsuperscript{55} MiR-28-5p was significantly downregulated in HCC and affected the metastasis of HCC through IL-34-mediated TAMs infiltration, suggesting that metastasis of HCC was regulated by the feedback loop of miR-28-5p-IL-34-macrophage.\textsuperscript{56} Clusters of miR-144/miR-451a promoted M1 polarization by targeting hepatocyte growth factor, predicting a better prognosis in HCC patients.\textsuperscript{57}

MiRNAs contained in CAFs-derived exosomes also regulate the tumor microenvironment. The content of miR-150-3p was significantly decreased in CAFs-derived exosomes. Using exosomes to transfer miR-150-3p from CAFs to HCC cells could inhibit HCC migration and invasion.\textsuperscript{58} HCC cells-derived miR-21 directly targeted PTEN to activate the PDK1/AKT signaling pathway in hematopoietic stem cells, thereby activating CAFs. The latter further promoted the progression of HCC through secreting angiogenic cytokines such as VEGF, bFGF, and transforming growth factor-β (TGF-β).\textsuperscript{59}

2.5 | MiRNAs and hepatocyte regeneration

The liver has a very high regenerative capacity. Liver regeneration is precisely regulated by a variety of molecular mechanisms. MiRNAs also play an essential role in the proliferation of regenerating hepatocytes. About 40% of miRNAs were upregulated 3h after partial hepatectomy as initiation signals for cell proliferation, including miRNAs that target miRNA synthesis such as Drosha, DGCR8, Dicer, and TRBP. At 24h after partial hepatectomy, about 70% of miRNAs were downregulated, providing negative feedback and promoting cell proliferation.\textsuperscript{60} Most miRNAs levels decreased within 3 days after partial hepatectomy. The cell cycle and cell proliferation-related genes expression increased correspondingly.\textsuperscript{61} MiR-21 is critical in liver regeneration. MiR-21 upregulation promoted hepatocyte proliferation via targeting PTEN and Ras homolog family member B, while Dicer1 deletion inhibited liver regeneration by downregulating miR-21.\textsuperscript{62,63} MiR-23b was highly expressed within 24h after partial hepatectomy. This could promote hepatocyte proliferation. However, a continued decline was observed at 3–7 days after surgery.\textsuperscript{64} Sustained overexpression of miR-34a, a tumor suppressor, was found 24h after partial hepatectomy.\textsuperscript{65} Thus, targeting miRNA and its related pathways may provide a new strategy to promote liver regeneration.

The list of miRNAs and their roles in HCC mentioned in this section is as follows (Table 1).

3 | MOLECULAR MECHANISMS OF MiRNAs IN REGULATING THE DEVELOPMENT OF HCC

MiRNAs have stable expression in vivo and can regulate key molecules closely related to the development of HCC through a variety of signaling pathways. Several key molecules and pathways regulated by miRNAs are summarized here.

3.1 | Transforming growth factor-β

Transforming growth factor-β is a critical enforcer for immune homeostasis and tolerance. The interference of TGF-β signaling is the basis of inflammatory diseases, which promotes the emergence of tumors. TGF-β expresses in almost all tumor cells and plays a vital role in tumor immune evasion and adverse reactions to immunotherapy.\textsuperscript{66,67} In HCC, TGF-β evades the tumor suppression by inducing specific miRNAs. MiR-23a was significantly upregulated and played anti-apoptotic and pro-proliferative effects in human HCC. TGF-β induced changes in the expression of miR-23a in HCC cells, which depended on the Smad2/3/4 signaling pathway.\textsuperscript{68,69} MiR-140-5p inhibited the proliferation and metastasis of HCC cells by targeting TGF-β receptor 1 (TGFB1). However, the miR-140-5p level was significantly decreased in HCC tissues, which was closely related to HCC cell differentiation, disease-free survival, and overall survival.\textsuperscript{70,71} MiRNAs can interact with long non-coding RNAs.
(lncRNAs) to regulate downstream target genes. In HCC, LncRNA AK002107 directly inhibited miR-140-5p to upregulate TGFBR1, thereby inducing epithelial-mesenchymal transition (EMT). LncRNA SBF2-AS1 also regulated the miR-140-5p-TGFB1 pathway to promote HCC progression.

3.2 | Receptor tyrosine kinases

Receptor tyrosine kinases (RTKs) are enzyme-linked receptors that also act as kinases, phosphorylating tyrosine residues of target proteins. The insulin receptor family, epidermal growth factor receptor family, vascular endothelial growth factor receptor family, platelet-derived growth factor receptor family, Eph receptor family, and neurotrophic factor receptor family all belong to RTKs. RTKs maintain a balance between cell proliferation and cell death under normal physiological conditions. Abnormal activation of RTKs leads to balance disruption and triggers RTKs-induced tumorigenesis.

MiRNAs can regulate the expression of RTKs directly. For example, miR-10a promoted HCC metastasis by directly targeting Eph tyrosine kinase receptor A4-mediated EMT. The miR-296-5p level was decreased in HCC tissues. MiR-296-5p overexpression suppressed the EMT, migration, and invasion of HCC cells by inhibiting the NRG1/ERBB2/ERBB3/RAS/MAPK/fra2 signaling pathway. LncRNA MYLK-AS1 activated the EGFR/HER2-ERK1/2 signaling pathway via targeting miR-424-5p, thereby promoting HCC growth and invasion.

3.3 | Wnt-β-catenin pathway

The typical Wnt-β-catenin pathway strictly controls hepatobiliary development, maturation, and zoning. In mature healthy livers, the Wnt-β-catenin pathway is primarily inactive but can be reactivated during cell renewal, regeneration, and in certain pathological conditions or malignancy conditions. The Wnt-β-catenin signaling pathway is frequently over-activated in HCC, and this over-activation is closely related to core events of EMT, angiogenesis, and...
chemotherapy or radiotherapy resistance. MiRNAs can regulate genes encoding key components of the Wnt-β-catenin signaling pathway in HCC. For example, miR-182-5p inhibited β-catenin degradation by targeting FoxO3 and enhanced the interaction between β-catenin and TCF4, thereby activating the Wnt/β-catenin signaling pathway. MiR-370a inhibited the activity of Wnt-β-catenin pathway by downregulating ubiquitin-4, thus reducing the proliferation and invasion of HCC cells. MiR-129-5p exerted a Wnt-dependent inhibitory role by directly targeting hepatoma-derived growth factor (HDGF).

3.4 | Notch signaling pathway

The Notch signaling pathway plays an essential role in the regulation of HCC cell injury/stress response and EMT. MiRNAs can regulate the expression of Notch signaling components and their interactions with other signaling pathways. MiR-3163 downregulated ADAM-17 to inhibit Notch cleavage and activation, thus increasing HCC cells sensitivity to sorafenib. MiR-449a directly targeted Notch1 to inhibit its translation, thereby regulating EMT and inhibiting HCC cells invasion.

3.5 | PI3K/Akt/mammalian target of rapamycin (mTOR) signaling pathway

The PI3K/Akt/mTOR pathway regulates cell proliferation and metabolism. Abnormal activation of the PI3K/Akt/mTOR pathway is closely related to pathological features of HCC. MiRNAs can regulate the proliferation, differentiation, apoptosis, and metabolism of HCC by targeting the PI3K/Akt/mTOR axis. A miRNAs-regulated proteins interaction network analysis revealed that miRNA-149 exerted tumor-suppressive effect by inhibiting the Akt/mTOR pathway in HCC. MiR-1914 suppressed HCC progression by inhibiting the GPR39-mediated PI3K/Akt/mTOR pathway. MiR-379-5p inhibited Akt by directly targeting focal adhesion kinase (FAK), thereby regulating EMT and metastasis of HCC.

4 | MiRNAs in the Diagnosis of HCC

The co-existence of hepatitis and cirrhosis often complicates the early diagnosis of liver cancer. The main blood markers for screening of liver cancer include AFP, abnormal prothrombin, and AFP-L3 variants. Advances in omics and analytical techniques have led to new biomarkers for the diagnosis of liver cancer, including osteopontin, Glypican-3, Golgi Protein-73, and miRNAs. They not only contribute to the early diagnosis but also contribute to the understanding of the pathogenesis of liver tumors.

The stable expression and diverse functions of miRNAs in the human genome make them candidates as diagnostic biomarkers for early cancer. Serum miR-130b and miR-15b were both upregulated in HCC. MiR-130b had a sensitivity of 87.7% and a specificity of 81.4% for detecting HCC, while miR-15b had an extremely high sensitivity of 98.3% but a low specificity of only 15.3%. Their combination as HCC biomarkers may be beneficial, especially for HCC patients with low AFP levels at an early stage. MiR-16-2 and miR-21-5p had high sensitivity and specificity in distinguishing HCC patients from healthy volunteers and patients with chronic hepatitis C. The expression of miR-16 and miR-122 was significantly increased in patients with early-stage HCC, which can be used as biomarkers for the diagnosis of early HCC. Plasma miR-224 level not only indicated liver tumors smaller than 18 mm but also might be a sensitive biomarker for monitoring tumor dynamics.

In addition to the expression patterns, several other characteristics of miRNAs render them biomarkers for HCC. First, miRNAs have good stability in circulating body fluids. Even abnormally expressed miRNAs remain highly stability and easily detected in the serum or plasma of HCC patients. Second, miRNAs are readily available and can also be extracted from saliva and urine. It has been reported that five miRNAs (miR-516-5p, miR-532, miR-618, miR-625, and miR-650) detected in urine can be used to screen patients at high risk of HCC. MiR-122, miR-483, and miR-335 can be used as biomarkers for early diagnosis of HCC without invasion. Studies in Egyptian patients showed that miR-122 and miR-483 were upregulated while miR-335 was downregulated in HCC patients compared with normal controls and HCV-infected patients.

5 | MiRNAs in the Treatment of HCC

MiRNAs are non-immunogenic in human and can be used in the treatment of liver cancer. Aiming at the role of miRNAs in the molecular pathological mechanism of liver cancer, the use of miRNAs mimics or inhibitors may improve the therapeutic effect.

Activation of NF-κB is crucial in mediating inflammation-induced tumor progression. A series of miRNAs targeting the NF-κB signaling pathway were screened. Among them, miR-127-5p was found to inhibit the NF-κB activity and its downstream signaling molecules by suppressing the nuclear translocation of p65. MiR-127-5p mimics suppressed NF-κB activity by targeting biliverdin reductase B (BLVRB), thus hindering the growth and colony formation of HCC cells and improving the therapeutic efficacy.

Vessels that encapsulated tumor cluster (VETC) is a typical vascular pattern in HCC that promotes the invasion of the entire tumor cell population into the bloodstream independently. Angiopoietin 2 is essential for VETC formation. Overexpression of miR-125b or miR-100 in HCC cells could reduce VETC formation in xenografts and inhibit the metastasis of xenografts in vivo.

MiRNA-based therapeutic strategies may alter the expression networks of HCC, thereby significantly affecting cell behavior and making it possible to cure HCC. Virus-based delivery system or non-viral systems including nanoparticles, lipid-based vesicles, exosomes, and liposomes can deliver miRNAs. Delivery of miR-26a using an exosomes-based nanosystem inhibited proliferation
of HCC.\textsuperscript{113} Targeted delivery of miR-199a-3p using self-assembled dipeptide nanoparticles or exosomes reduced HCC efficiently.\textsuperscript{115,116}

MiR-34a was a potent tumor suppressor and identified as a p53 target.\textsuperscript{117} A clinical study (Clinical Trial Registration: NCT01829971) using a miR-34a mimics (MRX34) in the treatment of solid tumors predominantly hepatocellular carcinoma was prematurely terminated due to severe immune-mediated adverse events that resulted in the death of 4 patients, but the results still showed dose-dependence of relevant target genes, providing a proof-of-concept for miRNA-based HCC treatment.\textsuperscript{118}

6 | MiRNAs in the prognostic assessment of HCC

Clinically, the commonly used indicators of prognosis for HCC include portal hypertension, liver function status, tumor status, and physical status. Still, in fact, these indicators cannot accurately determine the prognosis of patients. More accurate and reliable molecular indicators are necessary for assessing prognosis. Some miRNAs can precisely predict the prognosis of HCC.\textsuperscript{119}

A miRNA microarray analyses of serum samples from HCC patients before and after treatment validated four candidate miRNAs. Among them, the combination of miR-4443, miR-4530, and miR-4454 can predict the treatment response, the combination of miR-4530 and miR-4454 can predict the overall survival, and miR-4492 can distinguish patients’ complete response from partial response.\textsuperscript{120}

A miRNAs database containing clinical data for HCC prognostic assessment was established using TCGA (RNA-seq) database, GEO (Microarray) database, and PubMed. There were 55 miRNAs associated with overall survival in the TCGA database, among which miR-139, miR-149, and miR-3677 were the most significant. There were 84 miRNAs correlated with the overall survival in the GEO database, among which miR-31, miR-146B-3p, and miR-584 were the most significant. The establishment of this database provided rich guidance information for evaluating the prognosis of HCC patients.\textsuperscript{121}

MiRNAs that are abnormally expressed in chronic liver disease may also act as prognostic indicators for HCC. Serum miR-21 and miR-885-5p levels were significantly elevated in HCV-infected patients with cirrhosis. Serum miR-21 was a marker of HCV infection and may serve as a potential diagnostic marker for HCC, while serum miR-885-5p was an important marker of cirrhosis and a potential diagnostic marker of advanced liver injury in HCV-related chronic liver disease.\textsuperscript{122}

MiRNAs are also closely related to tumor recurrence after orthotopic liver transplantation (OLT). A miRNA microarray analysis confirmed that miRNA expression patterns were different in patients with HCC recurrent and patients without recurrent after OLT. Six miRNAs with high sensitivity and specificity for predicting HCC recurrence were screened, including miR-19a, miR-24, miR-126, miR-147, miR-223, and miR-886-5p, which were independent predictors of overall survival and relapse-free survival after OLT.\textsuperscript{123}

7 | Prospect

According to epidemiological statistics, the number of primary liver cancer cases and deaths in China is expected to reach 591,000 and 572,000, respectively, by 2040. The number of people over the age of 70 will also rise, and the direct medical expenses will also increase year by year.\textsuperscript{129,130} The development of new strategies for diagnosis, treatment, and prognosis assessment of liver cancer by utilizing the characteristics of miRNAs will help improve the treatment status of this disease.

Further research on miRNAs also brings many new challenges. The number of miRNAs is relatively large, and one miRNA may have multiple target genes. Up to now, the in-depth study of the role of miRNAs in the molecular pathological mechanism of different stages of liver cancer is not sufficient. In addition, there are differences among the genomes of different geographical populations. Therefore, more in-depth research, development, and utilization of miRNAs are needed for the precision medicine strategies for HCC.

Author Contributions

Yilong Zhou, Fan Liu, Chunyang Ma, and Qiong Cheng contributed to the writing of the manuscript. Qiong Cheng conceived and finalized the content of the manuscript. All authors reviewed, contributed to the revisions, and finalized the drafts.

Funding Information

This study was supported by a grant from the Science and Technology Project of Nantong City, No. JCTZ0132; the Natural Science Foundation of Jiangsu Higher Education Institutions of China, No. 20KJA310011; and a grant from the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).

Conflict of Interest

The authors declare there is no conflict of interest.

Data Availability Statement

The data that support the findings of this study are openly available.
CONSENT FOR PUBLICATION
All authors agree to publish this article.

ORCID
Qiong Cheng https://orcid.org/0000-0002-0209-9361

REFERENCES
1. Feng RM, Zong YN, Cao SM, Xu RH. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? Cancer Commun (Lond). 2019;39(1):22.
2. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843-854.
3. Correia de Sousa M, Gjorgjieva M, Dolicka D, Sobolewski C, Foti M. Deciphering miRNAs' action through miRNA editing. Int J Mol Sci. 2019;20(4):6249.
4. Roderburg C, Luedde T. Circulating microRNAs as markers of liver inflammation, fibrosis and cancer. J Hepatol. 2014;61(6):1434-1437.
5. Rupaimoole R, Calin GA, Lopez-Berestein G, Sood AK. microRNAs in cancer regulation in cancer cells and the tumor microenvironment. J Hematol Oncol. 2019;16(1):791-804.
6. Lee YS, Dutta A. MicroRNAs in cancer. Annu Rev Pathol. 2009;4:199-227.
7. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring, and therapeutics. A comprehensive review. EMBO Mol Med. 2012;4(3):143-159.
8. Esquela-Kerscher A, Slack FJ. Oncomirs – microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259-269.
9. Cao MQ, You AB, Zhu XD. miR-182-5p promotes hepatocellular carcinoma progression and induces cell apoptosis by targeting BBC3. Int J Mol Med. 2017;16(5):6360-6367.
10. Qiu C, Zha W, Fan R, Ding H, Xu Y, Wang C. MicroRNA-302a inhibits cell proliferation and invasion, and induces apoptosis in hepatocellular carcinoma. Mol Med Rep. 2017;16(5):6360-6367.
11. Liu E, Sun X, Li J, Zhang C. mir-30a-5p inhibits the proliferation, migration and invasion of melanoma cells by targeting SOX4. Mol Med Rep. 2018;18(2):2492-2498.
12. Zhang S, Mansoori B, Asghari S, et al. MicroRNAs in cancer cell death pathways: apoptosis and necroptosis. Free Radic Biol Med. 2019;139:1-15.
13. Lian YF, Huang YL, Wang JL, et al. Anillin is required for tumor growth and regulation of miR-15a/miR-16-1 in HBV-related hepatocellular carcinoma. Aging (Albany NY). 2018;10(8):1884-1901.
14. Song S, Yang Y, Liu M, et al. MiR-125b attenuates human hepatocellular carcinoma malignancy through targeting SIRT6. Am J Cancer Res. 2018;8(6):993-1007.
15. Shimahara K, Wang Z, Zhang M, et al. lin-14. Gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843-854.
16. Santekhadur PK, Das SK, Gredler R, et al. Multifunction protein staphylococcal nuclease domain containing 1 (SND1) promotes tumor angiogenesis in human hepatocellular carcinoma through novel pathway that involves nuclear factor κB and miR-221. J Biol Chem. 2012;287(17):13952-13958.
17. Garofalo M, Di Leva G, Romano G, et al. miR-221/222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell. 2009;16(6):498-509.
18. de Oliveira ARCP, Castanhole-Nunes MMU, Biselli-Chicote PM, et al. Differential expression of angiogenesis-related miRNAs and VEGFA in cirrhosis and hepatocellular carcinoma. Arch Med Sci. 2020;16(5):1150-1157.
19. Liao Y, Wang C, Yang Z, et al. Dysregulated Sp1/miR-130b-3p/HOXA5 axis contributes to tumor angiogenesis and progression of hepatocellular carcinoma. Theranostics. 2020;10(12):5209-5224.
20. Zhang Y, Ma H, Li L, Huang X, Liu C. MicroRNA-3064-5p sponged by MALAT1 suppresses angiogenesis in human hepatocellular carcinoma by targeting the FOXA1/CD24/Src pathway. FASEB J. 2020;34(1):66-81.
21. Xin TM, Tao LD, Zhang M, et al. Clinicopathological significance of MicroRNA-20b expression in hepatocellular carcinoma and regulation of HIF-1α and VEGF function on cell biological behaviour. Dis Markers. 2015;2015:325176.
22. Jing BQ, Ou Y, Zhao L, Xie Q, Zhang YX. Experimental study on the prevention of liver cancer angiogenesis via miR-126. Eur Rev Med Pharmacol Sci. 2017;21(22):5096-5100.
23. Berretta M, Rinaldi L, DiBenedetto F, et al. Angiogenesis inhibitors for the treatment of hepatocellular carcinoma. Front Pharmacol. 2016;7:428.
24. Zhang J, Qiao L, Liang N, Xie J, Luo H, Deng G. Vascular mimicry and tumor metastasis. J BUON. 2016;21(5):533-541.
25. Liu H, Tang T, Hu X, et al. miR-138-5p inhibits vascular mimicry by targeting the HIF-1. J Immunol Res. 2022;2022:7318950-7318910.
26. Bao S, Jin S, Wang C, Tu P, Hu K, Lu J. Androgen receptor suppresses vascular mimicry in hepatocellular carcinoma via circRNA7/miRNA7-5p/VE-cadherin/Notch4 signalling. J Cell Mol Med. 2020;24(23):14110-14120.
27. Wu CH, Chen CY, Yeh CT, Lin KH. Radiosensitization of hepatocellular carcinoma through targeting radio-associated MicroRNA. Int J Mol Sci. 2020;21(5):1859.
28. Zhang Y, Zheng L, Ding Y, et al. miR-20a induces cell radioresistance by activating the PTEN/Pi3K/Akt signaling pathway in hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2015;92(5):1132-1140.
29. Ma H, Yuan L, Li W, Xu K, Yang L. The LncRNA H19/miR-193a-3p axis modifies the radio-resistance and chemotherapeutic tolerance of hepatocellular carcinoma cells by targeting PSEN1. J Cell Biochem. 2018;119(10):8325-8335.
30. Jin Q, Li XJ, Cao PG. MicroRNA-26b enhances the radiosensitivity of hepatocellular carcinoma cells by targeting EphA2. Tohoku J Exp Med. 2016;238(2):143-151.
31. Wang J, Zhao H, Yu J, et al. MiR-320b/RAD21 axis affects hepatocarcinoma radiosensitivity to ionizing radiation treatment through DNA damage repair signaling. Cancer Sci. 2021;112(2):575-588.
39. Shao Y, Zhang D, Li X, et al. MicroRNA-203 increases cell radiosensitivity via directly targeting Bmi-1 in hepatocellular carcinoma. *Mol Pharm.* 2018;15(8):3205-3215.
40. Luo J, Si ZZ, Li T, et al. MicroRNA-146a-5p enhances radiosensitivity in hepatocellular carcinoma through replication protein A3-mediated activation of the DNA repair pathway. *Am J Physiol Cell Physiol.* 2019;316(3):C299-C311.
41. Liu HM, Tan HY, Lin Y, Xu BN, Zhao WH, Xie YA. MicroRNA-1271-p inhibits cell proliferation and enhances radiosensitivity by targeting CDK1 in hepatocellular carcinoma. *J Biochem.* 2020;167(5):513-524.
42. Shao Y, Song X, Jiang W, et al. MicroRNA-621 enhances autophagy and promotes sorafenib resistance of hepatocellular carcinoma via targeting FBXW7. *Int J Med Sci.* 2022;19(2):257-266.
43. Xu G, Bu S, Wang X, Ge H. MiR-122 radiosensitize hepatic cellular carcinoma cells by suppressing cyclin G1. *Int J Radiat Biol.* 2022;98(1):11-17.
44. Xu Y, Huang J, Ma L, et al. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways. *Cancer Lett.* 2016;371(2):171-181.
45. Li D, Wang T, Sun FF, et al. MicroRNA-375 represses tumor angiogenesis and reverses resistance to sorafenib in hepatocarcinoma. *Cancer Ther.* 2021;28(1-2):126-140.
46. Fornari F, Pollutri D, Patrizi C, et al. In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3-mediated apoptosis. *Clin Cancer Res.* 2017;23(14):3953-3965.
47. Moradi-Chaleshtori M, Hashemi SM, Soudi S, Bandehpour M, Mohammadi-Yeganeh S. Tumor-derived exosomal microRNAs and proteins as modulators of macrophage function. *J Cell Physiol.* 2019;234(6):7970-7982.
48. Baig MS, Roy A, Rajpoot S, et al. Tumor-derived exosomes in the regulation of macrophage polarization. *Inflamm Res.* 2020;69(5):435-451.
49. Chen C, Liu JM, Luo YP. MicroRNAs in tumor immunity: functional regulation in tumor-associated macrophages. *J Zhejiang Univ Sci B.* 2020;21(1):12-28.
50. Ismail N, Wang Y, Dakhllallah D, et al. Macrophage microvesicles induce macrophage differentiation and miR-223 transfer. *Blood.* 2013;121(6):984-995.
51. Huang F, Zhao JL, Wang L, et al. miR-148a-3p mediates Notch signaling to promote the differentiation and M1 activation of macrophages. *Front Immunol.* 2017;8:1327.
52. Ke M, Zhang Z, Cong L, et al. MicroRNA-148b-colony-stimulating factor-1 signaling-induced tumor-associated macrophage infiltration promotes hepatocellular carcinoma metastasis. *Biomed Pharmacother.* 2019;120:109523.
53. Zhou SL, Hu ZQ, Zhou ZJ, et al. miR-28-5p-IL-34-macrophage feedback loop modulates hepatocellular carcinoma metastasis. *Hepatology.* 2016;63(5):1560-1575.
54. Zhao J, Li H, Zhao S, et al. Epigenetic silencing of miR-144-445a cluster contributes to HCC progression via paracrine HGF/MIF-mediated TAM remodeling. *Mol Cancer.* 2021;20(1):46.
55. Yugawa K, Yoshizumi T, Mano Y, et al. Cancer-associated fibroblasts promote hepatocellular carcinoma progression through downregulation of exosomal miR-150-3p. *Eur J Surg Oncol.* 2021;47(2):384-393.
56. Zhou Y, Ren H, Dai B, et al. Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancer-associated fibroblasts. *J Exp Clin Cancer Res.* 2018;37(1):324.
57. Shu J, Kren BT, Xia Z, et al. Genomewide microRNA downregulation as a negative feedback mechanism in the early phases of liver regeneration. *Hepatology.* 2011;54(2):609-619.
58. Chen X, Murad M, Cui YY, et al. miRNA regulation of liver growth after 50% partial hepatectomy and small size grafts in rats. *Transplantation.* 2011;91(3):293-299.
59. Chen X, Song M, Chen W, et al. MicroRNA-21 contributes to liver regeneration by targeting PTEN. *Med Sci Monit.* 2016;22:83-91.
60. Lv T, Kong L, Jiang J, et al. Dicer1 facilitates liver regeneration in a manner dependent on the inhibitory effect of miR-21 on Pten and RhoB expression. *Life Sci.* 2019;232:116656.
61. Kwon Y, Kim M, Kim Y, Jung HS, Jeoung D. Exosomal microRNAs as mediators of cellular interactions between cancer cells and stromal cells. *Mol Ther.* 2019;27(2):355-364.
62. Shen J, Wang T, Xia Z, et al. Genomewide microRNA downregulation of caspase-3-mediated apoptosis. *PLOS One.* 2011;6(5):e20238.
63. Colak S, Ten Dijke P. Targeting TGF-β signaling in cancer. *Trends Cancer.* 2017;3(1):56-71.
64. Battle E, Massagué J. Transforming growth factor-β signaling in immunity and cancer. *Immunity.* 2019;50(4):924-940.
65. Huang S, He X, Ding J, et al. Upregulation of miR-23a approximately 27a approximately 24 decreases transforming growth factor-beta-induced tumor-suppressive activities in human hepatocellular carcinoma cells. *Int J Cancer.* 2008;123(4):972-978.
66. Bi JG, Zheng JF, Li Q, et al. MicroRNA-181a-5p suppresses cell proliferation by targeting Egr1 and inhibiting Egr1/TGF-β/Smad pathway in hepatocellular carcinoma. *Int J Biochem Cell Biol.* 2019;106:107-116.
67. Yang H, Fang F, Chang R, Yang L. MicroRNA-140-5p suppresses tumor growth and metastasis by targeting transforming growth factor-β receptor 1 and fibroblast growth factor 9 in hepatocellular carcinoma. *Hepatology.* 2013;58(1):205-217.
68. Luo J, Si ZZ, Li T, et al. MicroRNA-146a-5p enhances autophagy and promotes sorafenib resistance of hepatocellular carcinoma via targeting FBXW7. *Int J Med Sci.* 2022;19(2):257-266.
69. Xu G, Bu S, Wang X, Ge H. MiR-122 radiosensitize hepatic cellular carcinoma cells by suppressing cyclin G1. *Int J Radiat Biol.* 2022;98(1):11-17.
70. Xu Y, Huang J, Ma L, et al. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways. *Cancer Lett.* 2016;371(2):171-181.
71. Li D, Wang T, Sun FF, et al. MicroRNA-375 represses tumor angiogenesis and reverses resistance to sorafenib in hepatocarcinoma. *Cancer Ther.* 2021;28(1-2):126-140.
72. Fornari F, Pollutri D, Patrizi C, et al. In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3-mediated apoptosis. *Clin Cancer Res.* 2017;23(14):3953-3965.
73. Moradi-Chaleshtori M, Hashemi SM, Soudi S, Bandehpour M, Mohammadi-Yeganeh S. Tumor-derived exosomal microRNAs and proteins as modulators of macrophage function. *J Cell Physiol.* 2019;234(6):7970-7982.
74. Kwon Y, Kim M, Kim Y, Jung HS, Jeoung J. Exosomal microRNAs as mediators of cellular interactions between cancer cells and macrophages. *Front Immunol.* 2020;11:1167.
75. Baig MS, Roy A, Rajpoot S, et al. Tumor-derived exosomes in the regulation of macrophage polarization. *Inflamm Res.* 2020;69(5):435-451.
76. Chen C, Liu JM, Luo YP. MicroRNAs in tumor immunity: functional regulation in tumor-associated macrophages. *J Zhejiang Univ Sci B.* 2020;21(1):12-28.
77. Ismail N, Wang Y, Dakhllallah D, et al. Macrophage microvesicles induce macrophage differentiation and miR-223 transfer. *Blood.* 2013;121(6):984-995.
78. Huang F, Zhao JL, Wang L, et al. miR-148a-3p mediates Notch signaling to promote the differentiation and M1 activation of macrophages. *Front Immunol.* 2017;8:1327.
79. Ke M, Zhang Z, Cong L, et al. MicroRNA-148b-colony-stimulating factor-1 signaling-induced tumor-associated macrophage infiltration promotes hepatocellular carcinoma metastasis. *Biomed Pharmacother.* 2019;120:109523.
80. Zhou SL, Hu ZQ, Zhou ZJ, et al. miR-28-5p-IL-34-macrophage feedback loop modulates hepatocellular carcinoma metastasis. *Hepatology.* 2016;63(5):1560-1575.
85. Yu Y, Xu P, Cui G, et al. UBQLN4 promotes progression of HCC.

82. Perugorria MJ, Olaizola P, Labiano I, et al. Wnt-β-catenin signaling in liver development, health and disease. Nat Rev Gastroenterol Hepatol. 2019;16(2):121-136.

87. Yang B, Wang C, Xie H, et al. MicroRNA-3163 targets ADAM-17 and inhibits growth and migration of HCC. Mol Cancer. 2018;17(1):191.

93. Chen JS, Li HS, Huang JQ, et al. MicroRNA-379-5p inhibits tumor growth and angiogenesis in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2019;145(1):171-181.

99. Kladey RD, Cui X, Bulla GA, Brunt EM, Fimmel CJ. Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease. Hepatology. 2002;35(6):1431-1440.

104. Okajima W, Komatsu S, Ichikawa D, et al. Circulating microRNA profiles in plasma: identification of miR-224 as a prognostic marker. Biomarker Med. 2019;13(7):523-534.

113. Mahati S, Fu X, Ma X, Zhang H, Xiao L. Delivery of miR-26a using an exosomes-based nanosystem inhibited proliferation of hepatocellular carcinoma in vitro. Exp Cell Res. 2015;350(1):262-272.

100. El-Tawdi AH, Matboli M, Shehata HH, et al. Evaluation of circulating DNA and microRNA in non-invasive diagnosis of HBV- and HCV-related hepatocellular carcinoma. Int J Mol Sci. 2019;20(4):1007.

114. Dhungel B, Ramlogan-Steel CA, Layton CJ. Alpha-fetoprotein and/or liver ultrasound imaging for detection of hepatocellular carcinoma in patients with chronic hepatitis B. Cochrane Database Syst Rev. 2012;12:CD002799.

108. Abdalla MA, Haj-Ahmad Y. Promising candidate urinary MicroRNA biomarkers for the early detection of hepatocellular carcinoma among high-risk hepatitis C virus Egyptian patients. J Cancer. 2012;3:19-31.

121. Mahati S, Fu X, Ma X, Zhang H, Xiao L. Delivery of miR-26a using an exosomes-based nanosystem inhibited proliferation of hepatocellular carcinoma in vitro. Exp Cell Res. 2015;350(1):262-272.
117. Li WJ, Wang Y, Liu R, et al. MicroRNA-34a: potent tumor suppressor, cancer stem cell inhibitor, and potential anticancer therapeutic. Front Cell Dev Biol. 2021;9:640587.

118. Hong DS, Kang YK, Borad M, et al. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. 2020;122(11):1630-1637.

119. Murakami Y, Yasuda T, Saigo K, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene. 2006;25(17):2537-2545.

120. Pratama MY, Visintin A, Crocè LS, Tiribelli C, Pascut D. Circulatory miRNA as a biomarker for therapy response and disease-free survival in hepatocellular carcinoma. Cancers (Basel). 2020;12(10):2810.

121. Nagy Á, Lánckzy A, Menyhárt O, Győrffy B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep. 2018;8(1):9227.

122. Nasser MZ, Zayed NA, Mohamed AM, Attia D, Esmat G, Khairy A. Circulating microRNAs (miR-21, miR-223, miR-885-5p) along the clinical spectrum of HCV-related chronic liver disease in Egyptian patients. Arab J Gastroenterol. 2019;20(4):198-204.

123. Han ZB, Zhong L, Teng MJ, et al. Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantation. Mol Oncol. 2012;6(4):445-457.

124. Wu J, Wu Y, Luo Y, et al. Circulating miRNA-199a and miRNA-122 levels as potential diagnostic and prognostic biomarkers for hepatocellular carcinoma. Ann Clin Lab Sci. 2020;50(2):219-227.

125. Chang J, Nicolas E, Marks D, et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may down-regulate the high affinity cationic amino acid transporter CAT-1. RNA Biol. 2004;1(2):106-113.

126. Chen F, Zhang F, Liu Y, Cai C. Simply and sensitively simultaneous detection hepatocellular carcinoma markers AFP and miRNA-122 by a label-free resonance light scattering sensor. Talanta. 2018;186:473-480.

127. Ning Q, Liu YF, Ye PJ, et al. Delivery of liver-specific miRNA-122 using a targeted macromolecular prodrug toward synergistic therapy for hepatocellular carcinoma. ACS Appl Mater Interfaces. 2019;11(11):10578-10588.

128. Wischhusen JC, Chowdhury SM, Lee T, et al. Ultrasound-mediated delivery of miRNA-122 and anti-miRNA-21 therapeutically immunomodulates murine hepatocellular carcinoma in vivo. J Control Release. 2020;321:272-284.

129. Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun (Lond). 2021;41:1037-1048.

130. Cao MD, Wang H, Shi JF, et al. Disease burden of liver cancer in China: an updated and integrated analysis on multi-data source evidence. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(11):1848-1858.

How to cite this article: Zhou Y, Liu F, Ma C, Cheng Q. Involvement of microRNAs and their potential diagnostic, therapeutic, and prognostic role in hepatocellular carcinoma. J Clin Lab Anal. 2022;36:e24673. doi: 10.1002/jcla.24673